Theravance Biopharma TBPH Increase Decrease In Prepaid Clinical And Development Services
Increase Decrease In Prepaid Clinical And Development Services at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's increase decrease in prepaid clinical and development services.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's increase decrease in prepaid clinical and development services?
- Theravance Biopharma (TBPH) reported increase decrease in prepaid clinical and development services of -$73K in Q1 2025.
- How has Theravance Biopharma's increase decrease in prepaid clinical and development services changed year-over-year?
- Theravance Biopharma's increase decrease in prepaid clinical and development services decreased by 252.1% year-over-year, from $48K to -$73K.
- What is the long-term trend for Theravance Biopharma's increase decrease in prepaid clinical and development services?
- Over 3 years (2021 to 2024), Theravance Biopharma's increase decrease in prepaid clinical and development services has grown at a -42.1% compound annual growth rate (CAGR), from -$10.13M to -$1.97M.
- What does increase decrease in prepaid clinical and development services mean?
- This tracks the change in advance payments made to third-party vendors for clinical trials and research development services. It reflects the company's commitment to future R&D activities and the timing of cash outflows relative to service delivery. Monitoring this helps investors understand the pipeline investment cycle and potential near-term R&D expenditure trends.